343 related articles for article (PubMed ID: 9728644)
1. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid: an ovarian cancer marker.
Sedláková I; Vávrová J; Tosner J; Hanousek L
Eur J Gynaecol Oncol; 2008; 29(5):511-4. PubMed ID: 19051824
[TBL] [Abstract][Full Text] [Related]
3. [Lysophosphatidic acid in ovarian cancer patients].
Sedlákova I; Vávrová J; Tosner J; Hanousek L
Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis.
Cao L; Zhang Y; Fu Z; Dong L; Yang S; Meng W; Li Y; Zhang W; Zhang J; Zheng C; Zhu H; Fan L
J Obstet Gynaecol Res; 2015 Dec; 41(12):1951-8. PubMed ID: 26472266
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.
Sedláková I; Vávrová J; Tošner J; Hanousek L
Tumour Biol; 2011 Apr; 32(2):311-6. PubMed ID: 21061112
[TBL] [Abstract][Full Text] [Related]
8. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors.
Pozlep B; Meleh M; Kobal B; Verdenik I; Osredkar J; Kralj LZ; Meden-Vrtovec H
Eur J Gynaecol Oncol; 2007; 28(5):394-9. PubMed ID: 17966220
[TBL] [Abstract][Full Text] [Related]
9. Lysophospholipids are potential biomarkers of ovarian cancer.
Sutphen R; Xu Y; Wilbanks GD; Fiorica J; Grendys EC; LaPolla JP; Arango H; Hoffman MS; Martino M; Wakeley K; Griffin D; Blanco RW; Cantor AB; Xiao YJ; Krischer JP
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1185-91. PubMed ID: 15247129
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses.
Xiao Y; Chen Y; Kennedy AW; Belinson J; Xu Y
Ann N Y Acad Sci; 2000 Apr; 905():242-59. PubMed ID: 10818458
[TBL] [Abstract][Full Text] [Related]
11. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer.
Meleh M; Pozlep B; Mlakar A; Meden-Vrtovec H; Zupancic-Kralj L
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):287-91. PubMed ID: 17766199
[TBL] [Abstract][Full Text] [Related]
12. Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors.
Tokumura A; Tominaga K; Yasuda K; Kanzaki H; Kogure K; Fukuzawa K
Cancer; 2002 Jan; 94(1):141-51. PubMed ID: 11815970
[TBL] [Abstract][Full Text] [Related]
13. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
14. Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.
Bese T; Barbaros M; Baykara E; Guralp O; Cengiz S; Demirkiran F; Sanioglu C; Arvas M
J Gynecol Oncol; 2010 Dec; 21(4):248-54. PubMed ID: 21278887
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis.
Lu Z; Chen Y; Hu Z; Hu C
Int J Gynecol Cancer; 2015 Jan; 25(1):18-23. PubMed ID: 25398018
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis.
Li YY; Zhang WC; Zhang JL; Zheng CJ; Zhu H; Yu HM; Fan LM
Lipids Health Dis; 2015 Jul; 14():72. PubMed ID: 26174150
[TBL] [Abstract][Full Text] [Related]
17. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
18. Detection of the Ovarian Cancer Biomarker Lysophosphatidic Acid in Serum.
De La Franier B; Thompson M
Biosensors (Basel); 2020 Feb; 10(2):. PubMed ID: 32075013
[TBL] [Abstract][Full Text] [Related]
19. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
20. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
